Durect Operating Margin from 2010 to 2024
| DRRX Stock | USD 0.88 0.03 3.30% |
Check Durect financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Durect's main balance sheet or income statement drivers, such as Depreciation And Amortization of 140.6 K, Interest Expense of 1.9 M or Total Revenue of 8.1 M, as well as many indicators such as Price To Sales Ratio of 1.72, Dividend Yield of 0.0 or PTB Ratio of 1.0. Durect financial statements analysis is a perfect complement when working with Durect Valuation or Volatility modules.
Durect | Operating Margin |
Latest Durect's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Durect over the last few years. It is Durect's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Durect's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.57) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Durect Operating Margin Regression Statistics
| Arithmetic Mean | (8.70) | |
| Geometric Mean | 1.35 | |
| Coefficient Of Variation | (318.95) | |
| Mean Deviation | 13.35 | |
| Median | (1.27) | |
| Standard Deviation | 27.74 | |
| Sample Variance | 769.24 | |
| Range | 109 | |
| R-Value | 0.40 | |
| Mean Square Error | 695.12 | |
| R-Squared | 0.16 | |
| Significance | 0.14 | |
| Slope | 2.49 | |
| Total Sum of Squares | 10,769 |
Durect Operating Margin History
About Durect Financial Statements
Durect investors use historical fundamental indicators, such as Durect's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Durect. Please read more on our technical analysis and fundamental analysis pages.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Durect Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Durect Stock Analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.